Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation
| Autor: | Anthony R. Mato, Doris M. Ponce, Esperanza B. Papadopoulos, Oscar B Lahoud, Lindsey E. Roeker, Andrew D. Zelenetz, Sean M. Devlin, Juliet N. Barker, Boglarka Gyurkocza, Parastoo B. Dahi, James W. Young, Guenther Koehne, Sergio Giralt, Molly Maloy, Craig S. Sauter, Ann A. Jakubowski, Miguel Perales, Hugo Castro-Malaspina |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Transplantation Conditioning Clinical Trials and Observations medicine.medical_treatment Chronic lymphocytic leukemia Graft vs Host Disease Hematopoietic stem cell transplantation Disease Richter's transformation 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Internal medicine medicine Humans neoplasms Retrospective Studies business.industry Hematopoietic Stem Cell Transplantation Cancer Hematology Middle Aged Total body irradiation medicine.disease Leukemia Lymphocytic Chronic B-Cell Confidence interval 030220 oncology & carcinogenesis Reduced Intensity Conditioning business 030215 immunology |
| Zdroj: | Blood Adv |
| ISSN: | 2473-9537 2473-9529 |
| DOI: | 10.1182/bloodadvances.2020003726 |
| Popis: | Allogeneic hematopoietic stem cell transplantation (HSCT) may potentially cure patients with chronic lymphocytic leukemia (CLL) and Richter’s transformation (CLL-RT) or CLL without RT, but the impact of novel agents on HSCT is unclear. CLL-RT patients have a grave prognosis, and their outcomes after HSCT are uncertain. We conducted a retrospective analysis of all 58 CLL patients, including 23 CLL-RT patients, who underwent reduced intensity conditioning (RIC) HSCT at Memorial Sloan Kettering Cancer Center (New York, NY) between September 2006 and April 2017. With a median follow-up of 68 months (range, 24-147 months), 5-year progression-free survival (PFS) was 40% (95% confidence interval [CI], 28%-56%), and overall survival (OS) was 58% (95% CI, 48%-74%). The 1-year graft-versus-host disease/relapse-free survival (GRFS) was 38% (95% CI, 25%-50%). Patients with CLL-RT and CLL patients without RT had comparable outcomes. In both cohorts, treatment-sensitive response and ≤3 previous lines of therapy produced superior PFS and OS. Outcomes were agnostic to adverse cytogenetic and molecular features. Novel agents did not have a negative impact on HSCT outcomes. Total body irradiation (TBI)-containing RIC yielded inferior PFS, OS, and GRFS. CLL-RT patients older than age 55 years who had an HSCT Comorbidity Index score of ≥2 demonstrated inferior OS. This study, which is the largest series of RIC-HSCT for patients with CLL-RT, provides evidence supporting RIC-HSCT in early remission courses for patients with CLL-RT and poor-risk CLL patients. TBI-containing RIC should be considered with caution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|